opn  (Bioss)

Journal: NPJ Precision Oncology

Article Title: Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer

doi: 10.1038/s41698-026-01474-2

Figure Lengend Snippet: A Identification of four celltypes in the LLC TME by scRNA-seq. B Anti-SPP1 therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.

Article Snippet: Five days post-inoculation, mice with palpable tumors were randomly assigned to four treatment groups ( n = 4 per group) using a random number table : Control (PBS) , Anti-PD-1 (clone RMP1-14, Bio X Cell, #BE0146) , Anti-SPP1 (anti-mouse osteopontin antibody, clone 103D6, MCE), and Anti-SPP1 combined with Anti-PD-1.

Techniques: Control, Immunofluorescence

Journal: Bioactive Materials

Article Title: Dual-function thermoresponsive antibiotic-loaded hydrogel with antimicrobial and osteogenic properties for implant-related infection control

doi: 10.1016/j.bioactmat.2026.02.044

Figure Lengend Snippet: In vivo immunohistochemical analysis (n = 6). (A) Representative immunolabeling images of the Control, PNVCL, and PNVCL/TC 25 mg/mL groups showing osteopontin (OPN) and osteocalcin (OCN) expression (immunopositive cells indicated by black arrows). (B) Mean scores (0–3) ± standard deviation for OPN immunostaining. (C) Mean scores (0–3) ± standard deviation for OCN immunostaining. Bars indicate statistically significant differences between groups (p < 0.05; Tukey HSD test).

Article Snippet: Endogenous peroxidase activity was quenched by incubation with 3% hydrogen peroxide for 1 h, followed by blocking of nonspecific binding sites with 1% bovine serum albumin for 12 h. The sections were then incubated with goat anti-osteopontin and goat anti-osteocalcin primary antibodies (sc-21742 and sc-30044, respectively; Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: In Vivo, Immunohistochemical staining, Immunolabeling, Control, Expressing, Standard Deviation, Immunostaining